Certain areas of care delivery could potentially be transformed by the further development of cell and gene therapies (CGT), particularly Chimeric Antigen Receptor T-cell (CAR-T) therapy. CGT has the potential to revolutionize the treatment of multiple diseases—particularly blood and other cancers, immunodeficiencies, neurologic disorders and rare diseases. However, several barriers such as cost, time commitment, limited availability and drug shortages hinder widespread adoption and accessibility of CGT. As the growing disease burden in the U.S. intensifies patient morbidity and acuity, demand for CGT is likely to accelerate. However, supply from both a treatment and workforce perspective is not prepared to meet current, much less future, demand.
Read the full article: The Cell and Gene Patient Journey Is Determined by Access to Treatment Sites //
Source: https://www.trillianthealth.com/insights/the-compass/the-cell-and-gene-patient-journey-is-determined-by-access-to-treatment-sites